Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposure

25 Oct 2019

Abstract excerpt

INTRODUCTION: BRAFV600E activating mutation is the most frequent genetic abnormality in the pathogenesis of papillary thyroid carcinoma. We aimed to evaluate the association between BRAFV600E mutation and well-established prognostic clinicopathological characteristics as well as iodine exposure. MATERIAL AND METHODS: From 2000 to 2012, the data of PTC patients admitted to Dr. Lutfi Kirdar Kartal Education and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Thyroid and Parathyroid Surgery
Share to Thyroid Cancer Diagnosis and Treatment
Share to Thyroid Disorders and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 31135058
DOI: 10.5603/ep.a2019.0025

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E mutation in papillary thyroid cancer is correlated with adverse clinicopathological features but not with iodine exposurePMID 31135058Read ↗

The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.Semantic proximity Read ↗

The BRAF V600E mutation is a predictor of the effect of radioiodine therapy in papillary thyroid cancerSemantic proximity Read ↗

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.Semantic proximity Read ↗

The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.Semantic proximity Read ↗

The Relevance between Iodine Nutritional Status and BRAFV600E Mutation on Papillary Thyroid CancerSemantic proximity Read ↗

BRAF V600E Mutation Lacks Association with Poorer Clinical Prognosis in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

[BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].Semantic proximity Read ↗

Risk and Prognostic Factors for BRAFV600E Mutations in Papillary Thyroid Carcinoma.Semantic proximity Read ↗

Analysis of the association of BRAFV600E mutation and Ki-67 overexpression with clinical and pathological characteristics in papillary thyroid cancer.Semantic proximity Read ↗

Prevalence and Clinicopathological Significance of BRAF V600E Mutation in Papillary Thyroid Carcinoma: A Retrospective Cohort Study from Kerala, IndiaSemantic proximity Read ↗

[Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma].Semantic proximity Read ↗

Impact of BRAFV600E Mutation on Event Free Survival in Patients with Papillary Thyroid Carcinoma: A Retrospective Study in a Romanian PopulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.